Myriad Genetics (MYGN) Long-Term Investments (2010 - 2023)

Myriad Genetics (MYGN) has reported Long-Term Investments for 14 consecutive years, with $6.2 million the latest figure, recorded in Q2 2023.

• In Q2 2023, Long-Term Investments fell 92.1% year-over-year to $6.2 million; the TTM figure through Jun 2023 stood at $6.2 million (down 92.1% YoY), while the FY2022 annual figure was $54.8 million, down 7.12% from the prior year.
• Long-Term Investments eased to $6.2 million in Q2 2023 per MYGN's latest filing, from $30.4 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $78.5 million in Q2 2022 and bottomed at $6.2 million in Q2 2023.
• Historically, Long-Term Investments has averaged $42.8 million across 5 years, with a median of $45.2 million in 2020.
• Annual changes were most pronounced in 2022 — Long-Term Investments soared 494.96% — and 2023, when it sank 92.1%.
• Myriad Genetics' Long-Term Investments stood at $47.6 million in 2019, then tumbled by 55.88% to $21.0 million in 2020, then surged by 180.95% to $59.0 million in 2021, then decreased by 7.12% to $54.8 million in 2022, then slumped by 88.69% to $6.2 million in 2023.
• Business Quant data shows MYGN's Long-Term Investments at $6.2 million in Q2 2023, $30.4 million in Q1 2023, and $54.8 million in Q4 2022.